MATWIN (Maturation and Accelerating Translation With Industry) is a French open-innovation platform, fully-owned subsidiary of Unicancer, dedicated to supporting innovation in oncology. For more than ten years, its goal has been to help scientists and entrepreneurs evaluate and optimize opportunities to transform their research into product, for the benefit of the patient.
MATWIN main objectives are to select R&D innovative oncology projects with high technology transfer potential, drive asset identification and support the most promising ones in accelerating development and optimizing collaboration opportunities.
The process is based on a continuing partnership with major international companies working in oncology willing to benefit from the attractiveness of French research in oncology.
MATWIN’s call for proposals is permanently open to European academic teams or startups. According to their specific needs, applicants may benefit from one or several steps of the program:
- Access to assessment by 15-20 key international industrial and academic opinion leaders from the global oncology R&D department of MATWIN’s partners and EU renowned research centres)
- Personalised coaching to help optimising the project structuring and its industry-oriented R&D development plan,
- Access to a network of partners (major groups, biotechs, investors) looking for collaborations
+300 supported projects
+20 clinical trials started between 2017 and 2023
+50 stratups created post MATWIN support and +50 projects transferred to external partners
2023 Figures
MATWIN co-organise the annual European Oncology Partnering Convention MEET2WIN since 2015
